Higher plasma 5-hydroxyindoleacetic acid levels are associated with SSRI-induced nausea

Neuropsychobiology

Volumn 48, Issue 1, 2003, Pages 31-34

  Ueda, Nobuhisa ^a   Yoshimura, Reiji ^a   Shinkai, Koji ^a   Sakata, Yumi ^a   Nakamura, Jun ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

5 Hydroxyindoleacetic acid; Depression; Fluvoxamine; Nausea; Paroxetine

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; FEMALE; GASTROINTESTINAL TRACT; HEARTBURN; HUMAN; INTESTINE INNERVATION; MAJOR DEPRESSION; MALE; NAUSEA; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; SEROTONINERGIC SYSTEM; VOMITING;

ACETOPHENONES; ADULT; AGED; DEPRESSIVE DISORDER; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; NAUSEA; OXIMES; PAROXETINE; SEROTONIN UPTAKE INHIBITORS;

EID: 0042173194     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000071826     Document Type: Article

References (24)

1. Perugi G, Giannotti D, Di Vaio S, Frare F, Saettoni M, Cassano GB: Fluvoxamine in the treatment of body dysmorphic disorder (dys-morphobia). Int Clin Psychopharmacol 1996; 11:247-254.
2. Poyurovsky M, Isalov V, Hromnikov S, Modai I, Rauchberger B, Schneidman M, Weizman A: Fluvoxamine treatment of obsessive-compulsive symptoms in schizophrenic patients: An add-on open study. Int Clin Psychopharmacol 1999;14:95-100.
3. Wagstaff AJ, Cheer SM, Matheson AJ, Ormrod D, Goa KL: Paroxetine: An update of its use in psychiatric disorders in adults. Drugs 2002;62: 655-703.
4. Marangell LB, Silver JM, Martinez JM, Yudofsky SC: Concise Guide to Psychopharmacology. Washington, American Psychiatric Publishing, 2002.
5. Hori H, Yoshimura R, Nakamura J: Increased libido in a woman treated with fluvoxamine: A case report. Acta Psychiatr Scand 2001;103: 312-314.
6. Di Rocco A, Brannan T, Prikhojan A: Sertral-ine induced parkinsonism: A case report and an in-vivo study of the effect of sertraline on dopamine metabolism. J Neural Transm 1998; 105:247-251.
7. Linazasoro G: Worsening of Parkinson's disease by citalopram. Parkinsonism Relat Disord 2000;6:111-113.
8. Kakihara S, Ueda N, Yoshimura R, Nakamura J: A case of parkinsonism associated with fluvoxamine and lithium administration (in Japanese). Jpn J Clin Psychopharmacol 2001;4: 545-548.
9. Kasper S, Fuger J, Möller HJ: Comparative efficacy of antidepressants. Drugs 1992; 43(suppl 2):11-23.
10. Wilde MI, Plosker GL, Benfield P: Fluvoxamine: An updated review of its pharmacology, and therapeutic use in depressive illness. Drugs 1993;46:895-924.
11. Price JS, Waller PC, Wood SM, Mackay AVP: A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol 1996; 42:757-763.
12. Spigset O: Adverse reactions of selective serotonin reuptake inhibitors. Drug Saf 1999;20: 277-287.
13. Bergeron R, Blier P: Cisapride for the treatment of nausea produced by selective serotonin reuptake inhibitors. Am J Psychiatry 1994;151: 1084-1086.
14. Bailey JE, Potokar JP, Coupland NJ, Nutt DJ: The 5-HT3 antagonist ondansetron reduces gastrointestinal side effects induced by a specific serotonin re-uptake inhibitor in man. J Psychopharmacol 1995;9:137-141.
15. Sagrada A, Brancaccio N, Schiavone A: 5-Hydroxytryptamine affects rat migrating myoelectric complexes through different receptor subtypes: Evidence from 5-hydroxytrypto-phan administration. Life Sci 1990;46:1207-1216.
16. Cubeddu LX, Hoffmann LS, Fuenmayor NT, Finn AL: Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 1990;322:810-816.
17. Beck TM: The pattern of emesis following high-dose cyclophosphamide and the anti-emetic efficacy of ondansetron. Anticancer Drugs 1995;6:237-242.
18. Ueda N, Yoshimura R, Shinkai K, Terao T, Nakamura J: Characteristics of fluvoxamine-induced nausea. Psychiatry Res 2001;104:259-264.
19. Minegishi A, Ishizaki T: Determination of free 3-methoxy-4-hydroxyphenylglycol with several other monoamine metabolites in plasma by high-performance liquid chromatography with amperometric detection. J Chromatogr 1984; 311:51-57.
20. Gorard DA, Libby GW, Farthing MJG: 5-Hydroxytryptamine and human small intestinal motility; Effect of inhibiting 5-hydroxy-tryptamine reuptake. Gut 1994;35:496-500.
21. Markianos M, Botsis A, Arvanitis Y: Biogenic amine metabolites in plasma of drug-naïve schizophrenic patients: Associations with symptomatology. Biol Psychiatry 1992;32: 288-292.
22. Nagaoka S, Iwamoto N, Arai H: First-episode neuroleptics-free schizophrenics: Concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment. Biol Psychiatry 1997;41:857-864.
23. Cubeddu LX, Hoffmann IS, Fuenmayor NT, Malave JJ: Changes in serotonin metabolism in cancer patients: Its relationship to nausea and vomiting induced by chemotherapeutic drugs. Br J Cancer 1992;66:198-203.
24. Alfieri AB, Cubeddu LX: Treatment with para-chlorophenylalanine antagonises the emetic response and the serotonin-releasing actions of cisplatin in cancer patients. Br J Cancer 1995; 71:629-632.